Shiri Procaccia's research while affiliated with Technion - Israel Institute of Technology and other places

Publications (7)

Article
Full-text available
Introduction: As the medical use of Cannabis is evolving there is a greater demand for high-quality products for patients. One of the main steps in the manufacturing process of medical Cannabis is drying. Most current drying methods in the Cannabis industry are relatively slow and inefficient processes. Materials and Methods: This article presents...
Article
Full-text available
The use of medical cannabis (MC) to treat cancer-related symptoms is rising. However, there is a lack of long-term trials to assess the benefits and safety of MC treatment in this population. In this work, we followed up prospectively and longitudinally on the effectiveness and safety of MC treatment. Oncology patients reported on multiple symptoms...
Article
Full-text available
Medical Cannabis and its major cannabinoids (−)-trans-Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are gaining momentum for various medical purposes as their therapeutic qualities are becoming better established. However, studies regarding their efficacy are oftentimes inconclusive. This is chiefly because Cannabis is a versatile plant rathe...
Article
Full-text available
In the last decades, growing evidence showed the therapeutic capabilities of Cannabis plants. These capabilities were attributed to the specialized secondary metabolites stored in the glandular trichomes of female inflorescences, mainly phytocannabinoids and terpenoids. The accumulation of the metabolites in the flower is versatile and influenced b...
Article
Full-text available
Studies have shown that females are more susceptible to adverse effects (AEs) from conventional drugs. This study aimed to investigate the differences of Medical Cannabis (MC) related AEs between females and males in chronic non-cancer pain (CNCP) patients. This is a cross-sectional study of adult patients licensed for MC treatment who were also di...
Article
Medical cannabis (MC) treatment for chronic pain is increasing, but evidence regarding short-and long-term efficacy and associated adverse effects (AEs) of the different cannabis plant components is limited. Most reports focus on two phytocannabinoids, (-)-Δ 9-trans-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). This study, aimed to identify...
Article
Full-text available
In the last decade the use of medical cannabis (MC) for palliative cancer treatment has risen. However, the choice between products is arbitrary and most patients are using Tetrahydrocannabinol (THC)-dominant cannabis products. In this study, we aimed to assess the short-term outcomes of MC treatment prescribed by oncologists in relation to the typ...

Citations

... Monoterpenoids are built by two isoprene units (10 carbons) and sesquiterpenoids are built up by three isoprene units (15 carbons) (Shapira et al., 2019). Monoterpenoids and phytocannabinoids share the common biosynthetic precursor GPP and are both biosynthesized in the plastid, while sesquiterpenoids are synthesized in the cytosol from farnesyl pyrophosphate (Booth et al., 2020;Lipson Feder et al., 2021). Terpenoids are responsible for the fragrance and taste of plants as they are characterized by a strong and pleasant aroma (Gershenzon and Dudareva, 2007). ...
... Many of the measures that improved are associated with improved quality of life, which may suggest some of the effect of MC treatment on pain intensity was indirect, as previously discussed (51)(52)(53). Studies have shown that quality of life in patients that suffer from a severe illness such as cancer plays an important role in treatment adherence and success (54)(55)(56). ...
... Conversely, no prominent harmful effects have been reported in any of these articles. As for extracts, it has to be kept in mind that each has its own characteristics in terms of composition, anticancer potency and adverse reactions [91]. Caution is therefore advised as results may not be reproducible with another extract. ...
... Semi-structured interviews with medical specialist would be helpful in assessing their current beliefs. This is especially important in light of the great discordance between patient-perceived effects of cannabinoids and those effects retrieved from clinical trials, as also seen in the current study (Aviram et al. 2020;Good et al. 2019;Hardy et al. 2020). ...